Michaela Ann Dinan, PhD

Adjunct Professor in the Department of Population Health Sciences
Assistant Professor in Medicine
Membership in the Duke Clinical Research Institute
Campus mail 22 Johns Path, Madison, CT 06443
Phone (919) 668-8177
Email address michaela.dinan@duke.edu

Dr. Dinan is a health services researcher with a focus on emerging medical technology in cancer. Dr. Dinan currently holds an AHRQ K99/R00 pathway to independence award to examine adoption of Oncotype DX molecular testing in breast cancer and has conducted work in breast and other cancers examining emerging technologies and their associated disparities in utilization, outcomes and costs. Dr. Dinan has expertise in both secondary data analysis and clinical registry methodologies. Her secondary data expertise include the SEER-Medicare linked data, Medicare claims, NIS, NCDB, as well as EHR data.

Dr. Dinan holds additional appointments at the Duke Clinical Research Institute and Duke Cancer Institute where she co-leads the Patient Experience and Survivorship Focus Area in the Cancer Control and Population Sciences Program.

Areas of expertise: Health Economics, Health Policy, and Health Services Research

Education and Training

  • Ph.D., University of North Carolina - Chapel Hill, 2011
  • B.S., University of Virginia, 2003

Publications

Varma, Tanvee, Joshua D. Wallach, Jennifer E. Miller, Dominic Schnabel, Joshua J. Skydel, Audrey D. Zhang, Michaela A. Dinan, Joseph S. Ross, and Cary P. Gross. “Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics.” Jama Netw Open 4, no. 4 (April 1, 2021): e217063. https://doi.org/10.1001/jamanetworkopen.2021.7063.

PMID
33877309
Full Text

Wilson, Lauren E., Melissa A. Greiner, Ivy Altomare, Jason Rotter, and Michaela A. Dinan. “Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015.” J Geriatr Oncol 12, no. 3 (April 2021): 375–80. https://doi.org/10.1016/j.jgo.2020.11.007.

PMID
33250425
Full Text

Dinan, Michaela A., Mihaela V. Georgieva, Yanhong Li, Tian Zhang, Michael Harrison, Rahul Shenolikar, and Charles D. Scales. “Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.” J Geriatr Oncol 12, no. 2 (March 2021): 298–304. https://doi.org/10.1016/j.jgo.2020.08.005.

PMID
32912737
Full Text

Ramalingam, Sendhilnathan, Michaela A. Dinan, and Jeffrey Crawford. “Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung.” Clin Lung Cancer, January 7, 2021. https://doi.org/10.1016/j.cllc.2020.12.013.

PMID
33582071
Full Text

Moss, Haley A., Oyomoare Osazuwa-Peters, Michaela Dinan, Evan Myers, and Laura J. Havrilesky. “Leakage from Accountable Care Organizations Among Gynecologic Cancer Patients: Prevalence, Predictors, and Impact on Annual Medicare Expenditures.” In Journal of Womens Health, 29:A4–5, 2020.

Scholars@Duke

Dinan, Michaela A., Lauren E. Wilson, Shelby D. Reed, Jennifer J. Griggs, and Edward C. Norton. “Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption.” Clin Breast Cancer 20, no. 6 (December 2020): 487-494.e1. https://doi.org/10.1016/j.clbc.2020.05.010.

PMID
32653473
Full Text

Moss, Haley A., Laura J. Havrilesky, Frances F. Wang, Mihaela V. Georgieva, Laura H. Hendrix, and Michaela A. Dinan. “Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer.” J Oncol Pract 15, no. 12 (December 2019): e1018–27. https://doi.org/10.1200/JOP.19.00026.

PMID
31613721
Full Text

Zambeli-Ljepović, Alan, Frances Wang, Michaela A. Dinan, Terry Hyslop, Sanziana A. Roman, Julie Ann Sosa, and Randall P. Scheri. “Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage.” J Surg Res 243 (November 2019): 189–97. https://doi.org/10.1016/j.jss.2019.05.029.

PMID
31185435
Full Text

Zambeli-Ljepović, Alan, Frances Wang, Michaela A. Dinan, Terry Hyslop, Michael T. Stang, Sanziana A. Roman, Julie A. Sosa, and Randall P. Scheri. “Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in survival but not in short-term outcomes.” Surgery 166, no. 5 (November 2019): 895–900. https://doi.org/10.1016/j.surg.2019.05.035.

PMID
31288935
Full Text

Zambeli-Ljepovic, Alan, Frances Wang, Michaela A. Dinan, Terry Hyslop, Michael T. Stang, Sanziana A. Roman, Julie Ann Sosa, and Randall P. Scheri. “Low Risk Thyroid Cancer in Older Adults: More Extensive Surgery Comes with Increased Cost of Surveillance.” In Journal of the American College of Surgeons, 229:S78–S78. ELSEVIER SCIENCE INC, 2019.

Scholars@Duke

Pages